Skip to main content
Top
Published in: Clinical & Experimental Metastasis 6/2014

01-08-2014 | Research Paper

FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion

Authors: Timothy G. Whitsett, Shannon P. Fortin Ensign, Harshil D. Dhruv, Landon J. Inge, Paul Kurywchak, Kerri K. Wolf, Janine LoBello, Christopher B. Kingsley, Jeffrey W. Allen, Glen J. Weiss, Nhan L. Tran

Published in: Clinical & Experimental Metastasis | Issue 6/2014

Login to get access

Abstract

The five-year survival rate in advanced non-small cell lung cancer (NSCLC) remains below ten percent. The invasive and metastatic nature of NSCLC tumor cells contributes to the high mortality rate, and as such the mechanisms that govern NSCLC metastasis is an active area of investigation. Two surface receptors that influence NSCLC invasion and metastasis are the hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14). MET protein is over-expressed in NSCLC tumors and associated with poor clinical outcome and metastasis. FN14 protein is also elevated in NSCLC tumors and positively correlates with tumor cell migration and invasion. In this report, we show that MET and FN14 protein expressions are significantly correlated in human primary NSCLC tumors, and the protein levels of MET and FN14 are elevated in metastatic lesions relative to patient-matched primary tumors. In vitro, HGF/MET activation significantly enhances FN14 mRNA and protein expression. Importantly, depletion of FN14 is sufficient to inhibit MET-driven NSCLC tumor cell migration and invasion in vitro. This work suggests that MET and FN14 protein expressions are associated with the invasive and metastatic potential of NSCLC. Receptor-targeted therapeutics for both MET and FN14 are in clinical development, the use of which may mitigate the metastatic potential of NSCLC.
Literature
1.
go back to reference Jemal A et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMed Jemal A et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMed
2.
3.
go back to reference Stella GM, Benvenuti S, Comoglio PM (2010) Targeting the MET oncogene in cancer and metastases. Expert Opin Investig Drug 19(11):1381–1394CrossRef Stella GM, Benvenuti S, Comoglio PM (2010) Targeting the MET oncogene in cancer and metastases. Expert Opin Investig Drug 19(11):1381–1394CrossRef
4.
go back to reference Tsuta K et al (2012) c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol 7(2):331–339PubMedCrossRef Tsuta K et al (2012) c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol 7(2):331–339PubMedCrossRef
5.
go back to reference Yang Y et al (2008) A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 7(4):952–960PubMedCentralPubMedCrossRef Yang Y et al (2008) A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 7(4):952–960PubMedCentralPubMedCrossRef
6.
go back to reference Bean J et al (2007) MET amplification occurs with or without T790 M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104(52):20932–20937PubMedCentralPubMedCrossRef Bean J et al (2007) MET amplification occurs with or without T790 M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104(52):20932–20937PubMedCentralPubMedCrossRef
7.
go back to reference Benedettini E et al (2010) Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177(1):415–423PubMedCentralPubMedCrossRef Benedettini E et al (2010) Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177(1):415–423PubMedCentralPubMedCrossRef
8.
go back to reference Navab R et al (2009) Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 11(12):1292–1300PubMedCentralPubMed Navab R et al (2009) Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 11(12):1292–1300PubMedCentralPubMed
9.
go back to reference Feng SL et al (2000) The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 156(4):1253–1261PubMedCentralPubMedCrossRef Feng SL et al (2000) The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 156(4):1253–1261PubMedCentralPubMedCrossRef
10.
go back to reference Tran NL et al (2003) The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 162(4):1313–1321PubMedCentralPubMedCrossRef Tran NL et al (2003) The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 162(4):1313–1321PubMedCentralPubMedCrossRef
11.
go back to reference Tran NL et al (2006) Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res 66(19):9535–9542PubMedCrossRef Tran NL et al (2006) Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res 66(19):9535–9542PubMedCrossRef
12.
go back to reference Watts GS et al (2007) Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer 121(10):2132–2139PubMed Watts GS et al (2007) Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer 121(10):2132–2139PubMed
13.
go back to reference Willis AL et al (2008) The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 6(5):725–734PubMedCentralPubMedCrossRef Willis AL et al (2008) The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 6(5):725–734PubMedCentralPubMedCrossRef
14.
go back to reference Whitsett TG et al (2012) Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol 181(1):111–120PubMedCentralPubMedCrossRef Whitsett TG et al (2012) Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol 181(1):111–120PubMedCentralPubMedCrossRef
15.
go back to reference Fortin SP et al (2009) Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. Mol Cancer Res 7(11):1871–1881PubMedCentralPubMedCrossRef Fortin SP et al (2009) Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. Mol Cancer Res 7(11):1871–1881PubMedCentralPubMedCrossRef
16.
go back to reference Tran NL et al (2005) The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 280(5):3483–3492PubMedCrossRef Tran NL et al (2005) The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 280(5):3483–3492PubMedCrossRef
17.
go back to reference Zhou H et al (2011) Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Mol Cancer Ther 10(7):1276–1288PubMedCentralPubMedCrossRef Zhou H et al (2011) Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Mol Cancer Ther 10(7):1276–1288PubMedCentralPubMedCrossRef
18.
go back to reference Knudsen BS et al (2009) A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol 17(1):57–67PubMedCentralPubMedCrossRef Knudsen BS et al (2009) A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol 17(1):57–67PubMedCentralPubMedCrossRef
19.
go back to reference Jackson EL et al (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15(24):3243–3248PubMedCentralPubMedCrossRef Jackson EL et al (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15(24):3243–3248PubMedCentralPubMedCrossRef
20.
go back to reference Bardeesy N et al (2002) Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419(6903):162–167PubMedCrossRef Bardeesy N et al (2002) Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419(6903):162–167PubMedCrossRef
21.
go back to reference DuPage M, Dooley AL, Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4(7):1064–1072PubMedCentralPubMedCrossRef DuPage M, Dooley AL, Jacks T (2009) Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 4(7):1064–1072PubMedCentralPubMedCrossRef
22.
go back to reference Nakayama M et al (2003) Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 170(1):341–348PubMedCrossRef Nakayama M et al (2003) Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 170(1):341–348PubMedCrossRef
23.
go back to reference Fortin Ensign SP et al (2013) The Src homology 3 domain-containing guanine nucleotide exchange factor is overexpressed in high-grade gliomas and promotes tumor necrosis factor-like weak inducer of apoptosis-fibroblast growth factor-inducible 14-induced cell migration and invasion via tumor necrosis factor receptor-associated factor 2. J Biol Chem 288(30):21887–21897PubMedCentralPubMedCrossRef Fortin Ensign SP et al (2013) The Src homology 3 domain-containing guanine nucleotide exchange factor is overexpressed in high-grade gliomas and promotes tumor necrosis factor-like weak inducer of apoptosis-fibroblast growth factor-inducible 14-induced cell migration and invasion via tumor necrosis factor receptor-associated factor 2. J Biol Chem 288(30):21887–21897PubMedCentralPubMedCrossRef
24.
go back to reference Chuang YY et al (2004) Role of synaptojanin 2 in glioma cell migration and invasion. Cancer Res 64(22):8271–8275PubMedCrossRef Chuang YY et al (2004) Role of synaptojanin 2 in glioma cell migration and invasion. Cancer Res 64(22):8271–8275PubMedCrossRef
25.
go back to reference Ji H et al (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155):807–810PubMedCrossRef Ji H et al (2007) LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155):807–810PubMedCrossRef
26.
27.
go back to reference Franks LM et al (1976) Metastasizing tumors from serum-supplemented and serum-free cell lines from a C57BL mouse lung tumor. Cancer Res 36(3):1049–1055PubMed Franks LM et al (1976) Metastasizing tumors from serum-supplemented and serum-free cell lines from a C57BL mouse lung tumor. Cancer Res 36(3):1049–1055PubMed
28.
go back to reference Layton MG, Franks LM (1984) Heterogeneity in a spontaneous mouse lung carcinoma: selection and characterisation of stable metastatic variants. Br J Cancer 49(4):415–421PubMedCentralPubMedCrossRef Layton MG, Franks LM (1984) Heterogeneity in a spontaneous mouse lung carcinoma: selection and characterisation of stable metastatic variants. Br J Cancer 49(4):415–421PubMedCentralPubMedCrossRef
29.
go back to reference Birchmeier C et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915–925PubMedCrossRef Birchmeier C et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4(12):915–925PubMedCrossRef
30.
go back to reference Gherardi E et al (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12(2):89–103PubMedCrossRef Gherardi E et al (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12(2):89–103PubMedCrossRef
31.
go back to reference Webb CP et al (1998) Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 17(16):2019–2025PubMedCrossRef Webb CP et al (1998) Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. Oncogene 17(16):2019–2025PubMedCrossRef
32.
go back to reference Matteucci E, Bendinelli P, Desiderio MA (2009) Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis 30(6):937–945PubMedCrossRef Matteucci E, Bendinelli P, Desiderio MA (2009) Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis 30(6):937–945PubMedCrossRef
34.
go back to reference Sanz-Pamplona R et al (2011) Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2 + and ErbB-2- primary breast tumors. Am J Pathol 179(2):564–579PubMedCentralPubMedCrossRef Sanz-Pamplona R et al (2011) Expression of endoplasmic reticulum stress proteins is a candidate marker of brain metastasis in both ErbB-2 + and ErbB-2- primary breast tumors. Am J Pathol 179(2):564–579PubMedCentralPubMedCrossRef
35.
go back to reference Wang J et al (2013) Clinical correlations and prognostic relevance of Fn14 expression in breast carcinoma. Histol Histopathol 28(7):859–864PubMed Wang J et al (2013) Clinical correlations and prognostic relevance of Fn14 expression in breast carcinoma. Histol Histopathol 28(7):859–864PubMed
36.
go back to reference Eder JP et al (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15(7):2207–2214PubMedCrossRef Eder JP et al (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15(7):2207–2214PubMedCrossRef
37.
go back to reference Zhou H et al (2013) The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol 133(4):1052–1062PubMedCentralPubMedCrossRef Zhou H et al (2013) The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol 133(4):1052–1062PubMedCentralPubMedCrossRef
Metadata
Title
FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion
Authors
Timothy G. Whitsett
Shannon P. Fortin Ensign
Harshil D. Dhruv
Landon J. Inge
Paul Kurywchak
Kerri K. Wolf
Janine LoBello
Christopher B. Kingsley
Jeffrey W. Allen
Glen J. Weiss
Nhan L. Tran
Publication date
01-08-2014
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 6/2014
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-014-9653-6

Other articles of this Issue 6/2014

Clinical & Experimental Metastasis 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine